For years, hopeful parents around the globe turned to one prolific Danish sperm donor, trusting that rigorous medical checks kept everyone safe.
Now, dozens of families are confronting a frightening revelation: the donor carried a rare genetic mutation linked to childhood cancers, and nearly 200 children may have been exposed to it.
A super donor at the centre of a global scandal
Between 2006 and 2022, a Danish sperm donor using the pseudonym “Kjeld” became one of Europe’s most widely used donors. His samples were distributed by the European Sperm Bank, based in Denmark, one of the world’s largest providers of donor sperm.
In that 16‑year window, his sperm was shipped to 67 fertility clinics across 14 countries. According to Danish public broadcaster DR, these donations led to the conception of 197 children, including 99 born in Denmark and almost 100 in other countries.
Parents were assured that donors were thoroughly screened and medically safe. Few imagined that an undetected mutation could slip through.
For many couples facing infertility, “Kjeld” represented a lifeline. People who had struggled for years finally became parents thanks to his donations. Only later did some of these families learn that their child had developed cancer, triggering a chain of medical and regulatory questions that now spans several countries.
How the alarm was raised
The first warning came in April 2020, when the sperm bank was informed that a child conceived with the donor’s sperm had been diagnosed with cancer and was carrying a genetic mutation. At that point, it looked like a tragic but isolated case.
Three years later, a second, similar case appeared: another child, also conceived from the same donor, also diagnosed with cancer, also carrying a suspicious mutation. This time, doctors and the sperm bank could not dismiss the pattern.
Further investigations were ordered. Genetic tests were carried out on samples from the donor. Those tests revealed an anomaly that had been missed during the original screening process: a rare mutation in a crucial cancer‑related gene called TP53.
The discovery forced the sperm bank to confront a scenario that most clinics only know from theoretical risk assessments: a single donor transmitting a high‑risk mutation to a large group of children.
➡️ Psychology explains why emotional exhaustion can appear without obvious stress
➡️ A study suggests cats may develop a form of dementia similar to Alzheimer’s
➡️ The salt-in-dish-soap trick: the magic cocktail that solves a big kitchen problem
➡️ Psychology explains why emotional reactions can feel stronger in safe environments
➡️ Not Nivea or Neutrogena: the best moisturising cream brand according to this expert study
➡️ After six years of trials, Iceland’s four‑day week now attracts 90% of workers
➡️ 9 parenting attitudes that create unhappy children, according to psychology
What is the TP53 gene and why does it matter?
The TP53 gene holds the instructions to produce a protein called p53. This protein plays a vital role in protecting the body from cancer formation.
Sometimes described by scientists as the “guardian of the genome”, p53 constantly monitors the DNA inside cells. When DNA damage occurs, p53 can pause cell division, trigger repair mechanisms, or, if the damage is severe, push the cell to self-destruct.
That process helps prevent faulty cells from multiplying and turning into tumours. When TP53 is mutated, this protection system can break down.
A rare and unusual mutation
In many cancers, TP53 is mutated inside tumour cells. In some families, inherited TP53 mutations cause a syndrome that dramatically raises lifetime cancer risk. The case of the Danish donor is different again.
The European Sperm Bank explained that the donor carried a rare, previously undescribed TP53 mutation. Even more unusual: the mutation did not appear throughout his body.
The mutation was found only in a fraction of the donor’s sperm cells and not in his blood or other tissues, meaning he did not show signs of the disease himself.
This situation is consistent with what scientists call a “mosaic” mutation. In mosaicism, a genetic change appears in some cells of the body, but not all. If it arises during the formation of sperm cells, a man can pass the mutation to some of his children without having the mutation in his own blood or organs.
That helps explain why standard screening, often based on blood tests and family history, failed to catch the problem.
How many children are affected?
Nearly 200 children worldwide were conceived with this donor’s sperm. Not all of them received the mutation. For any single sperm cell, the mutation was either present or absent.
The sperm bank has not publicly confirmed how many children are known to carry the TP53 variant, nor how many have developed cancer. Some families have only recently been contacted and are waiting for genetic testing.
- 197 children conceived with the donor’s sperm
- 14 countries involved
- 67 clinics supplied between 2006 and 2022
- A rare TP53 mutation present only in part of the donor’s sperm
For families, the uncertainty can be as painful as a diagnosis. Many have healthy children and are now being told there may be an inherited risk that was never disclosed at the time of treatment.
What this reveals about sperm bank screening
Sperm banks routinely test donors for infectious diseases, basic genetic disorders such as cystic fibrosis, and sometimes a panel of more extensive conditions. They also take family histories and may exclude candidates with known cancer syndromes or serious inherited diseases.
Yet this case shows the limit of those safeguards. A rare mutation that exists only in a subset of sperm cells will not necessarily show up in a blood test, and the donor himself may have no symptoms and no family history.
Current screening is designed to catch common, well‑described genetic risks, not every rare mutation that might appear only in reproductive cells.
This raises uncomfortable questions for regulators and clinics:
- Should donors with very large numbers of offspring be restricted, to reduce the impact of any undetected risk?
- Do sperm banks need broader genetic panels, even if they raise costs and ethical dilemmas?
- How quickly should clinics notify families when a new mutation is found?
Emotional and legal fallout for families
Parents who used the donor typically trusted that screening meant “low risk”. Now, some are grappling with guilt, anxiety, and anger. They consented to treatment based on information that, while accurate at the time, turned out to be incomplete.
Questions are already emerging about responsibility and liability. Did the sperm bank respond promptly when the first cancer case appeared in 2020? Were clinics in all 14 countries notified at the same pace? Are families entitled to compensation for genetic testing, medical follow‑up, or psychological support?
| Stakeholder | Key concern |
|---|---|
| Parents | Health of child, access to testing, sense of trust and consent |
| Children | Long‑term cancer risk, insurance, future family planning |
| Sperm bank | Screening standards, notification duties, legal exposure |
| Clinics | Informing patients, managing records, revising donor limits |
What a TP53 mutation can mean for a child
A child who inherits a harmful TP53 mutation may face a higher risk of developing certain cancers early in life. That can include brain tumours, leukaemias, sarcomas or adrenal cancers, depending on the nature of the mutation.
Risk does not equal certainty. Many carriers stay well for years, especially with good surveillance. Yet knowing about the mutation usually leads doctors to recommend more frequent check‑ups and, in some cases, regular whole‑body scans or targeted imaging to catch cancers as early as possible.
For some families, genetic knowledge brings heavy anxiety. For others, it feels like a tool that offers a chance to act earlier and save lives.
Why infertility treatments rely heavily on trust
Infertility affects an estimated 15–25% of couples in France alone after a year of unprotected attempts, according to Inserm. Similar rates are seen across much of Europe and North America. Causes can lie with the woman, the man, or both partners.
On the male side, common issues include low sperm count, poor sperm quality, hormone problems, varicocele (dilated veins around the testicle), genetic anomalies, or infections. For many, donor sperm is the only realistic route to having a baby.
That creates a relationship of deep trust between patients and fertility services. Donor profiles, medical clearance, and clinic reputations weigh heavily on people who may already feel vulnerable and out of options.
What prospective parents can ask clinics
Cases like the Danish donor will remain rare, but they highlight some practical questions patients can raise with their clinic before treatment:
- What genetic tests are performed on donors, and how often are these panels updated?
- Is there a limit on the number of children that can be conceived from the same donor?
- How will we be contacted if new health information about the donor emerges years later?
- Can we access genetic counselling before and after treatment?
Fertility treatment already involves medical, financial and emotional risk. Asking direct questions helps shift some control back to patients and can reveal how seriously a clinic treats long‑term safety.
Looking ahead: genetic risk and future children
As genetic sequencing becomes cheaper, some experts suggest testing sperm and egg donors more extensively, possibly even sequencing their entire genomes. That approach could catch more rare variants like the TP53 mutation in Denmark, but it would raise new problems.
Extensive data can reveal countless variants of uncertain significance. Clinics would need policies on what to report, how to counsel patients, and where to draw the line between reasonable caution and paralysing over‑testing.
For children already conceived, targeted testing focused on the specific TP53 mutation makes more sense. Families can then decide, with a genetic counsellor, what level of monitoring fits their child’s risk and their own tolerance for medical interventions.
This case turns a distant theoretical risk into a concrete story that many parents can imagine: one donor, nearly 200 children, and a genetic change that nobody saw coming.
As regulators and clinics review their protocols, parents facing infertility today are left balancing hope against uncertainty, relying on questions, transparency and follow‑up to protect the families they are still trying so hard to build.